BIO vs SABSW · rev $651.0M vs P/E 0.0
BIO (BIO) versus SAB Biotherapeutics Inc (SABSW) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
SAB Biotherapeutics Inc (SABSW) common stock listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
SABSW does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. SABSW currently screens at market cap $0 and trailing P/E 0.0.
Not investment advice. Open the BIO and SABSW stock pages for the full models.
Not investment advice.